Amit V Pandey

Prof. Dr. Amit V Pandey

University of Bern, Bern, Switzerland
+1
orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2006 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
MKMartin Konrad
Martin Konrad
ASAndré Schaller
André Schaller
Dominik SeelowDominik Seelow
Dominik Seelow
Amit V PandeyAmit V Pandey
Amit V Pandey
SWSiegfried Waldegger
Siegfried Waldegger
SWStefanie Weber
Stefanie Weber

1 February 2004 in Nature Genetics
Verified
Journal Article
Open access
PDF file
CFChrista Fluck
Christa Fluck
TTToshihro Tajima
Toshihro Tajima
Amit V PandeyAmit V Pandey
Amit V Pandey
WAWiebke Arlt
Wiebke Arlt
KOKouji Okuhara
Kouji Okuhara
WMWalter L Miller
Walter L Miller
Deficient activities of multiple steroidogenic enzymes have been reported without and with Antley-Bixler syndrome (ABS), but mutations of corresponding cytochrome P450 enzymes have not been found. We identified mutations in POR, encoding P450 oxidoreductase, the obligate electron donor for these enzymes, in a woman with amenorrhea and three children with ABS, even though knock-out of POR is embryonically lethal in mice. Mutations of POR also affect drug-metabolizing P450 enzymes, explaining the association of ABS with maternal fluconazole ingestion.

1 May 2005 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
NHNingwu Huang
Ningwu Huang
Amit V PandeyAmit V Pandey
Amit V Pandey
VAVishal Agrawal
Vishal Agrawal
WRWilliam Reardon
William Reardon
PLPablo Lapunzina
Pablo Lapunzina
WMWalter L. Miller
Walter L. Miller

1 May 2013 in Pharmacology & Therapeutics
Verified
Journal Article
Closed access
Amit V PandeyAmit V Pandey
Amit V Pandey
CFChrista Fluck
Christa Fluck

1 August 2011 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
CFChrista Fluck
Christa Fluck
MMMonika Meyer-Böni
Monika Meyer-Böni
Amit V PandeyAmit V Pandey
Amit V Pandey
PKPetra Kempná
Petra Kempná
WMWalter L. Miller
Walter L. Miller
ABAnna Biason-Lauber
Anna Biason-Lauber

1 July 1999 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
Amit V PandeyAmit V Pandey
Amit V Pandey
BTBabu L. Tekwani
Babu L. Tekwani
RSRam L. Singh
Ram L. Singh
VCVirander S. Chauhan
Virander S. Chauhan
Endoperoxide antimalarials based on the ancient Chinese drug Qinghaosu (artemisinin) are currently our major hope in the fight against drug-resistant malaria. Rational drug design based on artemisinin and its analogues is slow as the mechanism of action of these antimalarials is not clear. Here we report that these drugs, at least in part, exert their effect by interfering with the plasmodial hemoglobin catabolic pathway and inhibition of heme polymerization. In an in vitro experiment we observed inhibition of digestive vacuole proteolytic activity of malarial parasite by artemisinin. These observations were further confirmed by ex vivo experiments showing accumulation of hemoglobin in the parasites treated with artemisinin, suggesting inhibition of hemoglobin degradation. We found artemisinin to be a potent inhibitor of heme polymerization activity mediated by Plasmodium yoelii lysates as well asPlasmodium falciparum histidine-rich protein II. Interaction of artemisinin with the purified malarial hemozoin in vitro resulted in the concentration-dependent breakdown of the malaria pigment. Our results presented here may explain the selective and rapid toxicity of these drugs on mature, hemozoin-containing, stages of malarial parasite. Since artemisinin and its analogues appear to have similar molecular targets as chloroquine despite having different structures, they can potentially bypass the quinoline resistance machinery of the malarial parasite, which causes sublethal accumulation of these drugs in resistant strains.